We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

45 hedge funds and large institutions have $203M invested in TCR2 Therapeutics Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

575% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 4

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

33% more capital invested

Capital invested by funds: $152M → $203M (+$50.7M)

13% more funds holding

Funds holding: 40 → 45 (+5)

Holders
45
Holders Change
+5
Holders Change %
+12.5%
% of All Funds
0.89%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
8
Increased
27
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$3.7M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$2.22M
3
Victory Capital Management
Victory Capital Management
Texas
+$1.14M
4
BlackRock
BlackRock
New York
+$931K
5
Millennium Management
Millennium Management
New York
+$776K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$1.11M
2
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$902K
3
Ameriprise
Ameriprise
Minnesota
-$21.6K
4
First Trust Advisors
First Trust Advisors
Illinois
-$7.99K
5
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management
Wisconsin
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$261K – – –
UBS Group
27
UBS Group
Switzerland
$206K +$84.7K +5,481 +61%
Squarepoint
28
Squarepoint
New York
$199K +$215K +13,937 New
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$183K +$98.9K +6,400 +100%
Barclays
30
Barclays
United Kingdom
$169K +$92.8K +6,000 +102%
M&T Bank
31
M&T Bank
New York
$159K +$172K +11,127 New
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$158K +$4.3K +278 +3%
AIG
33
American International Group
New York
$105K -$959 -62 -0.8%
Bank of America
34
Bank of America
North Carolina
$100K +$39.4K +2,550 +57%
Deutsche Bank
35
Deutsche Bank
Germany
$55K +$12.4K +801 +26%
Citigroup
36
Citigroup
New York
$44K +$36K +2,331 +325%
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$38.7K +$21.2K +1,370 +102%
TRCT
38
Tower Research Capital (TRC)
New York
$34K +$32.2K +2,082 +720%
Legal & General Group
39
Legal & General Group
United Kingdom
$29K +$649 +42 +2%
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
$21K +$7.1K +459 +45%
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$15K +$15.7K +1,018 +1,818%
AIP
42
Ameritas Investment Partners
Nebraska
$14K – – –
US Bancorp
43
US Bancorp
Minnesota
$6K – – –
MF
44
Manchester Financial
California
$3K +$3.09K +200 New
TFA
45
Toth Financial Advisory
Virginia
$2K – – –
Canada Pension Plan Investment Board
46
Canada Pension Plan Investment Board
Ontario, Canada
– -$902K -60,000 Closed
Northwestern Mutual Wealth Management
47
Northwestern Mutual Wealth Management
Wisconsin
– -$3K -200 Closed
Fidelity Investments
48
Fidelity Investments
Massachusetts
– -$1K -78 Closed
1
2

TCRR Hedge Fund Activity: Q4 2019 in Review

45 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q4 2019, worth a combined $203M — up 33% from $152M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TCRR positions and 3 closed out — a net gain of 5 holders — while 27 added to existing stakes and 4 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $3.7M. The largest seller was Artal Group, cutting an estimated $1.11M.

  • 45 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q4 2019, up from 40 in Q3 2019.
  • Funds reported $203M of TCR2 Therapeutics Inc. Common Stock stock for Q4 2019, up 33% quarter-over-quarter.
  • 8 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q4 2019 and 3 closed out, a net change of +5 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q4 2019 was EcoR1 Capital, an estimated $3.7M added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q4 2019 was Artal Group, an estimated $1.11M sold.

Based on aggregated 13F filings for Q4 2019.